CANbridge Pharmaceuticals (1228 HK)

Analysis

Health Care • China

CANbridge Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of transformative therapies for rare diseases and oncology. The company offers approved drugs such as Hunterase for Hunter syndrome and Livmarli for Alagille syndrome, and is developing a pipeline of gene therapies and other assets. It was founded in 2012 and is headquartered in Suzhou, China.

Refresh

Exchange Announcement • 25 Sep 2026 19:51

Interim Report 2026

Exchange Announcement • 31 Aug 2026 12:22

Interim Results Announcement For The Six Months Ended June 30, 2026

Exchange Announcement • 28 Aug 2026 17:31

Interim Results Announcement For The Six Months Ended June 30, 2026

Exchange Announcement • 18 Aug 2026 06:11

Voluntary Announcement - Nhia Reimbursement Approval Of Livmarli In Taiwan

Exchange Announcement • 17 Aug 2026 22:25

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Interim Report 2026

Interim Results Announcement For The Six Months Ended June 30, 2026

Interim Results Announcement For The Six Months Ended June 30, 2026

Voluntary Announcement - Nhia Reimbursement Approval Of Livmarli In Taiwan

Date Of Board Meeting